Lupus Nephritis — Renal Resistive Index as a Marker of Severity and Treatment Outcomes in Lupus Nephritis
Citation(s)
Boddi M, Natucci F, Ciani E The internist and the renal resistive index: truths and doubts. Intern Emerg Med. 2015 Dec;10(8):893-905. doi: 10.1007/s11739-015-1289-2. Epub 2015 Sep 4. Review.
Corapi KM, Dooley MA, Pendergraft WF 3rd Comparison and evaluation of lupus nephritis response criteria in lupus activity indices and clinical trials. Arthritis Res Ther. 2015 Apr 28;17:110. doi: 10.1186/s13075-015-0621-6. Review.
Krumme B Renal Doppler sonography--update in clinical nephrology. Nephron Clin Pract. 2006;103(2):c24-8. Epub 2006 Mar 10. Review.
Rees F, Doherty M, Grainge MJ, Lanyon P, Zhang W The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies. Rheumatology (Oxford). 2017 Nov 1;56(11):1945-1961. doi: 10.1093/rheumatology/kex260. Review.
Sugiura T, Nakamori A, Wada A, Fukuhara Y Evaluation of tubulointerstitial injury by Doppler ultrasonography in glomerular diseases. Clin Nephrol. 2004 Feb;61(2):119-26.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
